How to buy NLS Pharmaceutics stock | $3.45

NLS Pharmaceutics AG is a biotechnology business based in the US. NLS Pharmaceutics shares (NLSP) are listed on the NASDAQ and all prices are listed in US Dollars.

NLS Pharmaceutics stock price (NASDAQ: NLSP)

Use our graph to track the performance of NLSP stocks over time.

NLS Pharmaceutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$3.45
52-week range	$2.06 - $4.70
50-day moving average	$3.12
200-day moving average	$3.33
Wall St. target price	$10.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy NLS Pharmaceutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy NLS Pharmaceutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of NLS Pharmaceutics AG by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NLS Pharmaceutics price performance over time

Historical closes compared with the close of $3.45 from 2021-05-28

1 week (2021-07-21)	N/A
1 month (2021-07-01)	10.22%
3 months (2021-04-30)	-5.74%
6 months (2021-01-28)	N/A

1 year (2020-07-28)	N/A
2 years (2019-07-28)	N/A
3 years (2018-07-28)	N/A
5 years (2016-07-28)	N/A

NLS Pharmaceutics financials

Gross profit TTM	$0
Return on assets TTM	-150.64%
Return on equity TTM	0%
Profit margin	0%
Book value	N/A
Market capitalisation	$33.1 million

TTM: trailing 12 months

Shorting NLS Pharmaceutics shares

There are currently 51,834 NLS Pharmaceutics shares held short by investors – that's known as NLS Pharmaceutics's "short interest". This figure is 37.8% up from 37,610 last month.

There are a few different ways that this level of interest in shorting NLS Pharmaceutics shares can be evaluated.

NLS Pharmaceutics's "short interest ratio" (SIR)

NLS Pharmaceutics's "short interest ratio" (SIR) is the quantity of NLS Pharmaceutics shares currently shorted divided by the average quantity of NLS Pharmaceutics shares traded daily (recently around 647925). NLS Pharmaceutics's SIR currently stands at 0.08. In other words for every 100,000 NLS Pharmaceutics shares traded daily on the market, roughly 80 shares are currently held short.

To gain some more context, you can compare NLS Pharmaceutics's short interest ratio against those of similar companies.

• Jazz Pharmaceuticals (JAZZ.US): 6.92
• Novartis (NVS.US): 3.8
• Teva Pharmaceutical Industries (TEVA.US): 4.08

However NLS Pharmaceutics's short interest can also be evaluated against the total number of NLS Pharmaceutics shares, or, against the total number of tradable NLS Pharmaceutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NLS Pharmaceutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 NLS Pharmaceutics shares in existence, roughly 0 shares are currently held short) or 0.0086% of the tradable shares (for every 100,000 tradable NLS Pharmaceutics shares, roughly 9 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NLS Pharmaceutics.

Find out more about how you can short NLS Pharmaceutics stock.

NLS Pharmaceutics share dividends

We're not expecting NLS Pharmaceutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Novartis (NVS.US) (3.72% forward annual dividend yield)

NLS Pharmaceutics overview

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland. .

Frequently asked questions

What percentage of NLS Pharmaceutics is owned by institutions?
Currently 0.629% of NLS Pharmaceutics shares are held by institutions. When does the fiscal year end for NLS Pharmaceutics?
NLS Pharmaceutics's fiscal year ends in December. Where is NLS Pharmaceutics based?
NLS Pharmaceutics's address is: Alter Postplatz 2, Stans, Switzerland, 6370